Stable dosage forms of spiro and dispiro 1,2,4-trioxolane antimalarials
The field of the invention relates to stable dosage forms comprising spiro or dispiro 1,2,4-trioxolane antimalarials, or their pharmaceutically acceptable salts, prodrugs and analogues, and processes for their preparation. The water content of the dosage form is not more than 6.5% w/w.
1. A stable oral solid dosage form comprising; (a) cis-adamantane-2-spiro-3′-8′-[[[(2′-amino-2′-methylpropyl)amino]carbonyl]-methyl]-1′,2′,4′-trioxaspiro[4.5]decane hydrogen maleate (Active compound I); (b) piperaquine; and (c) one or more pharmaceutically acceptable excipients; wherein the dosage form is prepared by a dry process.
2. The stable oral solid dosage form according to claim 1 , wherein the dosage form comprises; (a) Active compound I in an amount of from about 5% to about 25%; and (b) piperaquine in an amount from about 40% to about 80% w/w based on the total weight of the dosage form.
3. The stable oral solid dosage form according to claim 1 , wherein the pharmaceutically acceptable excipient is selected from the group consisting of binders, diluents, glidants/lubricants, disintegrants, surfactants and coloring agents.
4. The stable oral solid dosage form according to claim 3 , wherein the diluent is microcrystalline cellulose.
5. The stable oral solid dosage form according to claim 1 , wherein the dosage form has dissolution performance such that more than 70% w/w of the Active compound I dissolves within 45 minutes, in a pH 4.5 acetate buffer with 2% tween 80, in USP type II apparatus.
6. The stable oral solid dosage form according to claim 1 , wherein the Active compound I and piperaquine are present in a weight ratio of from about 1:1 to about 1:10.
7. The stable oral solid dosage form according to claim 1 , wherein the Active compound I is present in a dose range of about 100 mg to about 300 mg and piperaquine is present in a dose range of about 700 mg to about 850 mg.
8. The stable oral solid dosage form according to claim 1 , wherein the dosage form comprises: (a) Active compound I in an amount of from about 5% to about 25%; (b) piperaquine in an amount of from about 40% to about 80%; (c) diluent in an amount of from about 10% to about 40%; (d) disintegrant in an amount of from about 1% to about 10%; and (e) lubricant in an amount of from about 1% to about 5% w/w based on the total weight of the dosage form.
9. The stable oral solid dosage form according to claim 1 , wherein the dosage form comprises: (a) Active compound I; (b) piperaquine; (c) microcrystalline cellulose as a diluent; (d) crospovidone as a disintegrant; and (e) magnesium stearate as a lubricant.
10. The stable oral solid dosage form according to claim 1 , wherein the dosage form comprises: (a) Active compound I in an amount of from about 5% to about 25%; (b) piperaquine in an amount of from about 40% to about 80%, and (c) microcrystalline cellulose in an amount of from about 10% to about 40% w/w based on the total weight of the dosage form.
11. The stable oral solid dosage form according to claim 1 , wherein the dosage form comprises Active compound I and microcrystalline cellulose in a weight ratio of from about 1:1 to about 1:5.
12. The stable oral solid dosage form according to claim 1 , wherein the dosage form is selected from a group consisting of tablet, capsule, pill, granule and powder.
13. The stable oral solid dosage form according to claim 12 , wherein the tablet is coated with one or more functional and or non-functional coating layers comprising film-forming polymers and coating additives.
14. The stable oral solid dosage form according to claim 13 , wherein the coating additives comprise one or more of plasticizers, glidants or flow regulators, opacifiers and lubricants.
15. The stable oral solid dosage form according to claim 1 , wherein the dosage form is processed and stored at a temperature below 27° C. and relative humidity 50%.
16. The stable oral solid dosage form according to claim 1 , wherein the dry process comprises direct compression or dry granulation.
17. The stable oral solid dosage form according to claim 1 , wherein the dosage form is prepared by a process comprising the steps of: (a) blending Active compound I, piperaquine, and one or more intragranular excipients; (b) milling, grinding or sieving the blend by roller compaction to form granules; (c) blending the granules with one or more extragranular excipients; (d) compressing the blend into tablets or filling into capsules.
18. The stable oral solid dosage form according to claim 1 , wherein the dosage form is prepared by a process comprising the steps of: (a) blending Active compound I, piperaquine, and one or more intragranular excipients; (b) granulating the blend by slugging; (c) blending the granules with one or more extragranular excipients; (d) compressing the blend into tablets or filling into capsules.
19. The stable oral solid dosage form according to claim 1 , wherein the dosage form is prepared is prepared by a process comprising the steps of: (a) blending Active compound I, piperaquine, and one or more pharmaceutically acceptable excipients; and (b) directly compressing the blend into tablets or filling into capsules.
20. The stable oral solid dosage form according to claim 1 , wherein the dosage form is prepared by a process comprising the steps of: (a) granulating a blend of one or more excipients; (b) drying the excipient granules; (c) blending excipient granules with Active compound I and piperaquine; and (d) compressing the blend into tablets or filling into capsules.
21. A method of treatment of malaria, the method comprising administering a stable oral solid dosage form comprising: (a) Active compound I; (b) piperaquine; and (c) one or more pharmaceutically acceptable excipients, wherein the dosage form is prepared by a dry process.